1. Home
  2. OMER

OMER

Omeros Corporation

Logo Omeros Corporation

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-23-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Founded: N/A Country:
N/A
Employees: N/A City: SEATTLE
Market Cap: 178.5M IPO Year: 2009
Target Price: N/A AVG Volume (30 days): 512.7K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.88 EPS Growth: N/A
52 Week Low/High: $0.92 - $7.80 Next Earning Date: 01-01-0001
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks:

Stock Insider Trading Activity of Omeros Corporation (OMER)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Demopulos Peter A MD OMER Director Nov 15 '23 Buy $1.53 10,000 $15,300.00 208,516 SEC Form 4